<DOC>
	<DOCNO>NCT01453998</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , safety reactogenicity booster vaccine dose 2 new formulation DTPa-HBV-IPV/Hib administer 12 15 month age , immune persistence follow primary series . All child booster study receive primary vaccination 2 , 3 4 month age study 113948 ( NCT01248884 ) . No new subject enrol booster study .</brief_summary>
	<brief_title>Safety Immunogenicity Booster Dose New Formulations GlaxoSmithKline Biologicals ' DTPa-HBV-IPV/Hib Vaccine ( GSK217744 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects participate study 113948 ( NCT01248884 ) receive three dos new license DTPaHBVIPV/Hib study vaccine . A male female child , include , 12 15 month age time booster vaccination . Subjects investigator believe parent ( ) / Legally Acceptable Representative ( ) ( LAR ( ) ) comply requirement protocol ( e.g . completion diary card , return followup visit ) . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period . Participation another clinical study within three month prior enrolment present booster study time present booster study , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Evidence previous intercurrent diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis Hib vaccination disease since conclusion visit study 113948 ( NCT01248884 ) . Serious chronic illness . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History reaction hypersensitivity likely exacerbate component vaccine . History neurological disorder seizure . Administration immunoglobulins and/or blood product within 3 month precede booster dose study vaccine plan administration study period . Occurrence follow event follow previous administration study vaccine constitute absolute contraindication dose . Anaphylactic hypersensitivity reaction . Encephalopathy define acute , severe central nervous system disorder occur within 7 day follow vaccination generally consist major alteration consciousness , unresponsiveness , generalized focal seizure persist hour , failure recover within 24 hour . Temperature ≥ 40.0°C ( axillary ) 40.5°C ( rectal ) within 48 hour vaccination , due another identifiable cause . Collapse shocklike state ( hypotonichyporesponsive episode ) within 48 hour vaccination . Persistent , inconsolable cry occur within 48 hour vaccination last ≥ 3 hour . Seizures without fever occur within 3 day vaccination . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : • Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C oral , axillary tympanic setting , ≥ 38.0° rectal setting . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>